COGENT BIOSCIENCES ANNOUNCES OVERSUBSCRIBED $225 MILLION PRIVATE PLACEMENT Pro-forma cash, cash equivalents and marketable securities expected to fund the Company into 2027 and through clinical readouts from ongoing SUMMIT, PEAK and APEX registration-directed trials...
Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer — Vepdegestrant is an investigational PROteolysis Targeting Chimera (PROTAC®) protein degrader designed to...
Recent Comments